TY - JOUR
T1 - Genomic analysis of multidrug-resistant Escherichia coli from North Carolina community hospitals
T2 - Ongoing circulation of CTX-M-producing ST131-H30Rx and ST131-H30R1 Strains
AU - Kanamori, Hajime
AU - Parobek, Christian M.
AU - Juliano, Jonathan J.
AU - Johnson, James R.
AU - Johnston, Brian D.
AU - Johnson, Timothy J.
AU - Weber, David J.
AU - Rutala, William A.
AU - Anderson, Deverick J.
N1 - Funding Information:
We are grateful to Veronika L. Tchesnokova and Evgeni V. Sokurenko for their assistance with assignment of gyrA, parC, and parE alleles. We also acknowledge Nicole Stoesser for providing her list of virulence sequences. The opinions expressed here are strictly ours and do not necessarily reflect those of our respective institutions or the Department of Veterans Affairs. H.K. received financial support from a Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellowship for Research Abroad. C.M.P. was supported by NIH training grant AI109979. This material is also based in part on work supported by Office of Research and Development, Medical Research Service, Department of Veterans Affairs grant 1 I01 CX000920-01 (J.R.J.). D.J.A. received support from the NIH/NIAID (K23AI095357). J.R.J. has ST131-related research grants from Actavis/Allergan, Merck, and Tetra-phase; a consultancy with Janssen/Crucell; and patent applications for tests related to specific E. coli strains. We report no other conflicts of interest relevant to this article.
Publisher Copyright:
© 2017 American Society for Microbiology. All Rights Reserved.
PY - 2017/8
Y1 - 2017/8
N2 - Escherichia coli sequence type 131 (ST131) predominates globally among multidrug-resistant (MDR) E. coli strains. We used whole-genome sequencing (WGS) to investigate 63 MDR E. coli isolates from 7 North Carolina community hospitals (2010 to 2015). Of these, 39 (62%) represented ST131, including 37 (95%) from the ST131-H30R subclone: 10 (27%) from its H30R1 subset and 27 (69%) from its H30Rx subset. ST131 core genomes differed by a median of 15 (range, 0 to 490) single-nucleotide variants (SNVs) overall versus only 7 within H30R1 (range, 3 to 12 SNVs) and 11 within H30Rx (range, 0 to 21). The four isolates with identical core genomes were all H30Rx. Epidemiological and clinical characteristics did not vary significantly by strain type, but many patients with MDR E. coli or H30Rx infection were critically ill and had poor outcomes. H30Rx isolates characteristically exhibited fluoroquinolone resistance and CTX-M-15 production, had a high prevalence of trimethoprim-sulfamethoxazole resistance (89%), sul1 (89%), and dfrA17 (85%), and were enriched for specific virulence traits, and all qualified as extraintestinal pathogenic E. coli. The high overall prevalence of CTX-M-15 appeared to be possibly attributable to its association with the ST131-H30Rx subclone and IncF[F2:A1:B] plasmids. Some phyloge-netically clustered non-ST131 MDR E. coli isolates also had distinctive serotypes/fimH types, fluoroquinolone mutations, CTX-M variants, and IncF types. Thus, WGS analysis of our community hospital source MDR E. coli isolates suggested ongoing circulation and differentiation of E. coli ST131 subclones, with clonal segregation of CTX-M variants, other resistance genes, Inc-type plasmids, and virulence genes.
AB - Escherichia coli sequence type 131 (ST131) predominates globally among multidrug-resistant (MDR) E. coli strains. We used whole-genome sequencing (WGS) to investigate 63 MDR E. coli isolates from 7 North Carolina community hospitals (2010 to 2015). Of these, 39 (62%) represented ST131, including 37 (95%) from the ST131-H30R subclone: 10 (27%) from its H30R1 subset and 27 (69%) from its H30Rx subset. ST131 core genomes differed by a median of 15 (range, 0 to 490) single-nucleotide variants (SNVs) overall versus only 7 within H30R1 (range, 3 to 12 SNVs) and 11 within H30Rx (range, 0 to 21). The four isolates with identical core genomes were all H30Rx. Epidemiological and clinical characteristics did not vary significantly by strain type, but many patients with MDR E. coli or H30Rx infection were critically ill and had poor outcomes. H30Rx isolates characteristically exhibited fluoroquinolone resistance and CTX-M-15 production, had a high prevalence of trimethoprim-sulfamethoxazole resistance (89%), sul1 (89%), and dfrA17 (85%), and were enriched for specific virulence traits, and all qualified as extraintestinal pathogenic E. coli. The high overall prevalence of CTX-M-15 appeared to be possibly attributable to its association with the ST131-H30Rx subclone and IncF[F2:A1:B] plasmids. Some phyloge-netically clustered non-ST131 MDR E. coli isolates also had distinctive serotypes/fimH types, fluoroquinolone mutations, CTX-M variants, and IncF types. Thus, WGS analysis of our community hospital source MDR E. coli isolates suggested ongoing circulation and differentiation of E. coli ST131 subclones, with clonal segregation of CTX-M variants, other resistance genes, Inc-type plasmids, and virulence genes.
KW - CTX-M
KW - Community hospitals
KW - Extended-spectrum β-lactamase (ESBL)
KW - Multidrug-resistant (MDR) Escherichia coli
KW - Whole-genome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85026402738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026402738&partnerID=8YFLogxK
U2 - 10.1128/AAC.00912-17
DO - 10.1128/AAC.00912-17
M3 - Article
C2 - 28584139
AN - SCOPUS:85026402738
SN - 0066-4804
VL - 61
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 8
M1 - e00912
ER -